However, despite the fact that IFX and anti-TNF blockers have been used in IBD and other immune mediated diseases for decades, the association between antigenic TNF-α and IFX PK is very limited, although high levels of TNF-α at baseline or during treatment serves as a sink for IFX thereby promoting underexposure, inadequate disease control, as reported previously in IBD [8] and rheumatoid arthritis [9]. Here, TNF is linked to rheumatoid arthritis.